Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

被引：25
|
作者：
Pemmaraju, Naveen [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, POB 301402, Houston, TX 77230 USA
来源：
CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2017年 / 12卷 / 06期
关键词：
BPDCN; IL3R; CD123; Targeted therapy; Bromodomain; BCL2; NFkB; WORLD-HEALTH-ORGANIZATION; T-CELLS; MYELOID NEOPLASMS; RECEPTOR-ALPHA; LEUKEMIA; TRANSPLANTATION; CLASSIFICATION; INHIBITION; REVISION;
D O I：
10.1007/s11899-017-0425-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：510 / 512
页数：3
相关论文
共 50 条
  • [1] Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
    Naveen Pemmaraju
    Current Hematologic Malignancy Reports, 2017, 12 : 510 - 512
  • [2] Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm
    Xue, Tongyuan
    Budde, L. Elizabeth
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (03) : 575 - +
  • [3] Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Economides, Minas P.
    Rizzieri, David
    Pemmaraju, Naveen
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (06) : 515 - 522
  • [4] CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm
    Bole-Richard, Elodie
    Pemmaraju, Naveen
    Cael, Blandine
    Daguindau, Etienne
    Lane, Andrew A.
    CANCERS, 2022, 14 (09)
  • [5] Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)
    Wilson, Nathaniel R.
    Pemmaraju, Naveen
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (04) : 431 - 438
  • [6] Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123
    Zanotta, Serena
    Galati, Domenico
    De Filippi, Rosaria
    Pinto, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [7] Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Minas P. Economides
    David Rizzieri
    Naveen Pemmaraju
    Current Hematologic Malignancy Reports, 2019, 14 : 515 - 522
  • [8] Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
    Pemmaraju, Naveen
    Deconinck, Eric
    Mehta, Priyanka
    Walker, Irwin
    Herling, Marco
    Garnache-Ottou, Francine
    Gabarin, Nadia
    Campbell, Clinton J. V.
    Duell, Johannes
    Moshe, Yakir
    Mughal, Tariq
    Mohty, Mohamad
    Angelucci, Emanuele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : e130 - e137
  • [9] Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy
    Wilson, Nathaniel R.
    Konopleva, Marina
    Khoury, Joseph D.
    Pemmaraju, Naveen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 734 - 740
  • [10] Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations
    Shumilov, Evgenii
    Mazzeo, Paolo
    Ghandili, Susanne
    Kuenstner, Axel
    Weidemann, Soeren
    Banz, Yara
    Stroebel, Philipp
    Pollak, Matthias
    Kolloch, Lina
    Beltraminelli, Helmut
    Kerkhoff, Andrea
    Mikesch, Jan-Henrik
    Schliemann, Christoph
    Haase, Detlef
    Wulf, Gerald
    Legros, Myriam
    Lenz, Georg
    Feldmeyer, Laurence
    Pabst, Thomas
    Witte, Hanno
    Gebauer, Niklas
    Bacher, Ulrike
    ANNALS OF HEMATOLOGY, 2024, 103 (05) : 1587 - 1599
12345